Novartis’ Kisqali bests AZ’ Faslodex in breast cancer trial
Adding Kisquali to Faslodex resulted in an almost 30% reduction in risk of death compared to Faslodex alone
Read More
Tag: Kisquali
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
